Article
Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hosts
2023-09-08
Abstract excerpt
<h4>Background</h4> Immunocompromised patients with COVID-19 have higher morbidity and mortality than general population. Some authors have successfully used antiviral combination, but never in the early phase of the infection. <h4>Methods</h4> Retrospective cohort study to describe efficacy and safety of the combination of 2 antivirals, with or without a mAb, both in early (within 10 days from symptoms) and in la...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 999fe7b3-f3e5-55fd-9dc8-2a1f6fd7d9f0
- DOI
- 10.1101/2023.09.07.23295202
